Compare Amgen, Inc. (AMGN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Trip.com Group Ltd — how do they compare? Amgen, Inc. trades at $356.69 (market cap $196.12B), while Trip.com Group Ltd trades at $42.51 (market cap $26.45B). The key difference: Amgen, Inc. is far larger — about 7.4× Trip.com Group Ltd's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TCOM | |
|---|---|---|
Market Cap | $196.12B | $26.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $78.96 |
52-Week Low | $271.18 | $39.84 |
Enterprise Value | $241.41B | $19.15B |
Dividend Yield | 2.77% | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Trip.com Group (TCOM) trades at $42.80, up 3.31% on the day, with strong fundamentals including a P/E of 6.43 and net income margin of 48.65%. The stock faces technical headwinds with a bearish signal from moving averages and RSI at 82.74 suggesting overbought conditions. Recent Q1 2026 earnings missed expectations at $0.83 vs. $0.85, while revenue guidance for Q2 2026 of 3%-8% growth disappointed investors, triggering an 18% selloff on June 29, 2026.
Despite near-term pressure from regulatory scrutiny and conservative guidance, Trip.com maintains robust profitability and analyst consensus of $56.72 price target with 67% buy ratings. The company's dominant position in China's travel market and strong cash flow generation provide long-term upside potential, though regulatory risks and margin compression remain key concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
